Targeted Therapies for Acute Myeloid Leukemia
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Pharmacogenetics".
Deadline for manuscript submissions: closed (31 January 2021) | Viewed by 3277
Special Issue Editor
Interests: cancer; hematological malignancies; molecular oncology; precision medicine; biomarker fiscovery; genomic and transcriptomic analyses; next generation sequencing; high throughput screening; translational cancer research; systems biology; drug repositioning
Special Issue Information
Dear Colleagues,
For the past several decades, the standard of care for acute myeloid leukemia (AML) has been a non-selective, cytotoxic, two-drug combination. However, with improved molecular testing and the sequencing of AML genomes, we have much better understanding of the heterogeneity of the disease, can classify AML into several different molecular subtypes, and now have the capacity to develop multiple targeted therapies. This has never been so evident as the past two years when 8 drugs have been approved for AML. Some target a defined molecular subgroup while others are approved for a certain setting. These include small molecule inhibitors for patients with activating mutations to fms-like tyrosine kinase 3 (FLT3) and for patients with mutations to isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2). Patients with CD33+ AML can be treated with an antibody drug conjugate, while patients ineligible for intensive chemotherapy now have a BCL2 inhibitor and Hedgehog pathway inhibitor as options. In addition to these, several more promising targeted therapies are being investigated for AML including epigenetic modifiers, p53 activators, multiple kinase inhibitors as well as immunotherapies. The aim of this Special Issue is to highlight the latest advances in the development of targeted therapies for AML and provide information that can help guide the use of these new drugs and personalize AML patient treatment.
Dr. Caroline Heckman
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Acute myeloid leukemia (AML)
- Targeted therapy
- Personalized medicine
